Cargando…

Endogenous n-3 PUFAs Improve Non-Alcoholic Fatty Liver Disease through FFAR4-Mediated Gut–Liver Crosstalk

The gut–liver axis plays a key role in the development and progression of non-alcoholic fatty liver disease (NAFLD). Due to the complexity and incomplete understanding of the cross-talk between the gut and liver, effective therapeutic targets are largely unknown. Free fatty acid receptors (FFARs) ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Xuan, Yang, Qin, Qu, Hongyan, Chen, Yongquan, Zhu, Shenglong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919706/ https://www.ncbi.nlm.nih.gov/pubmed/36771292 http://dx.doi.org/10.3390/nu15030586

Ejemplares similares

Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology
por: Zhao, Jiahui, et al.
Publicado: (2023)

FFAR2-FFAR3 receptor heteromerization modulates short-chain fatty acid sensing
por: Ang, Zhiwei, et al.
Publicado: (2018)

Molecular characterization of free fatty acid receptors FFAR2 and FFAR3 in the domestic cat
por: Yamamoto, Ichiro, et al.
Publicado: (2020)

The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
por: Li, Zhonglin, et al.
Publicado: (2023)

A Low ω-6 to ω-3 PUFA Ratio (n–6:n–3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth
por: Van Name, Michelle A, et al.
Publicado: (2020)

Omega-3 Fatty Acids and FFAR4
por: Oh, Da Young, et al.
Publicado: (2014)

Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
por: Lefere, Sander, et al.
Publicado: (2019)

Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease
por: Carbajo-Pescador, Sara, et al.
Publicado: (2019)

Non-alcoholic fatty liver and the gut microbiota
por: Bashiardes, Stavros, et al.
Publicado: (2016)

Molecular mechanism of fatty acid activation of FFAR1
por: Kumari, Punita, et al.
Publicado: (2023)

Effect of short chain fatty acids on the expression of free fatty acid receptor 2 (Ffar2), Ffar3 and early-stage adipogenesis
por: Frost, G, et al.
Publicado: (2014)

Gut-liver crosstalk in sepsis-induced liver injury
por: Sun, Jian, et al.
Publicado: (2020)

Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
por: Poeta, Marco, et al.
Publicado: (2017)

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
por: Yang, Keungmo, et al.
Publicado: (2023)

Gut Dysfunction and Non-alcoholic Fatty Liver Disease
por: Grabherr, Felix, et al.
Publicado: (2019)

Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease
por: Fabisiak, Adam, et al.
Publicado: (2020)

Metformin acts in the gut and induces gut-liver crosstalk
por: Tobar, Natália, et al.
Publicado: (2023)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice
por: Kang, Kai, et al.
Publicado: (2021)

Regulation of Cholesterol Metabolism in Liver: Link to NAFLD and Impact of n-3 PUFAs
por: Bae, Jin-Sik, et al.
Publicado: (2013)

Organ–Organ Crosstalk and Alcoholic Liver Disease
por: Poole, Lauren G., et al.
Publicado: (2017)

N-3 Polyunsaturated Fatty Acids (PUFAs) Reverse the Impact of Early-Life Stress on the Gut Microbiota
por: Pusceddu, Matteo M., et al.
Publicado: (2015)

Non-alcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2014)

Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2022)

Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2021)

Correction: N-3 Polyunsaturated Fatty Acids (PUFAs) Reverse the Impact of Early-Life Stress on the Gut Microbiota
por: Pusceddu, Matteo M., et al.
Publicado: (2015)

Long-Chain Polyunsaturated Fatty Acids n−3 (n−3 LC-PUFA) as Phospholipids or Triglycerides Influence on Epinephelus marginatus Juvenile Fatty Acid Profile and Liver Morphophysiology
por: de Mello, Paulo H., et al.
Publicado: (2022)

Correction: Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver
por: Ko, Masayoshi, et al.
Publicado: (2023)

The role of the gut microbiome and exercise in non-alcoholic fatty liver disease
por: Houttu, Veera, et al.
Publicado: (2020)

Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
por: Zhou, Jin, et al.
Publicado: (2021)

Free Fatty Acid Receptors (FFARs) in Adipose: Physiological Role and Therapeutic Outlook
por: Al Mahri, Saeed, et al.
Publicado: (2022)

Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4)
por: Kiepura, Anna, et al.
Publicado: (2021)

Human and mouse monocytes display distinct signalling and cytokine profiles upon stimulation with FFAR2/FFAR3 short-chain fatty acid receptor agonists
por: Ang, Zhiwei, et al.
Publicado: (2016)

Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
por: Pezzino, Salvatore, et al.
Publicado: (2022)

New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)
por: Zhang, Xu, et al.
Publicado: (2017)

Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy
por: Yan, Qianqian, et al.
Publicado: (2022)

FFAR from the Gut Microbiome Crowd: SCFA Receptors in T1D Pathology
por: Priyadarshini, Medha, et al.
Publicado: (2021)

Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis
por: Takayama, Shun, et al.
Publicado: (2021)

Research Progress on the Therapeutic Effect of Polysaccharides on Non-Alcoholic Fatty Liver Disease through the Regulation of the Gut–Liver Axis
por: Chen, Xiang, et al.
Publicado: (2022)

N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease
por: Khoshbaten, Manouchehr, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_k9cr8ju9ihpff90c3avfqo4nei